# Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06819735/  
OnCo record `nct06819735` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DT-7012 in advanced solid tumours, run by Domain Therapeutics Australia Pty Ltd, now recruiting.

## Summary

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06819735 by Domain Therapeutics Australia Pty Ltd, with 125 participants planned, started 2025-06-25 and due to reach its primary completion in 2027-09. Interventions recorded: DT-7012 and Immune checkpoint inhibitor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06819735
- Phase: 1/2
- Setting: A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (DOMISOL, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)
- Sponsor: Domain Therapeutics Australia Pty Ltd
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT06819735: https://clinicaltrials.gov/study/NCT06819735

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06819735.json